10/15/2026
“The patient satisfaction data further supports the exciting potential of the Vanquish technology,” said Dr. Arvin George, director of Prostate Cancer Programs at the Johns Hopkins Brady Urological Institute and a V***R 2 co-principal investigator. “Most patients experienced no pain, quickly resumed daily activities, and indicated high rates of satisfaction with their procedure and decision at 12months.”
Echoing V***R 2 Study results: 93% of patients were extremely satisfied or satisfied at 12 months, with minimal to no pain reported.
The Vanquish® System is cleared for thermal ablation of targeted prostate tissue via transurethral approach.
🔗 More: francismedical.com
Rx Only. FDA Cleared. See francismedical.com for safety information.